Upstream Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Upstream Bio, Inc.'s 2025 Annual Meeting of Stockholders held on June 10, 2025. The record date for the meeting was April 14, 2025, with 53,688,703 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on two proposals, both of which were approved:
- Proposal 1 (Election of Directors): Stockholders elected Erez Chimovits and Marcella Kuhlman Ruddy as Class I directors to serve until the 2028 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the selection of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the specific terms of the director appointments for Erez Chimovits and Marcella Kuhlman Ruddy in the Definitive Proxy Statement filed April 17, 2025.
- Confirm the engagement letter details with PwC for the 2025 fiscal year audit.
- Review the breakdown of broker non-votes (1,296,674 shares) to understand potential voting power dynamics.